Shionogi

FDA Approves First New Flu Drug in Nearly 20 Years
FDA Approves First New Flu Drug in Nearly 20 Years
CP Wire
FDA
Xofluza
Flu
Shionogi
Roche
Tamiflu
Flag link:
FDA Approves First New Flu Drug in Nearly 20 Years
Shionogi
Roche
Xofluza
Tamiflu
influenza
Flag link:
Fast-acting flu drug shows strong potential, but clinical trial results also raise concerns
Fast-acting flu drug shows strong potential, but clinical trial results also raise concerns
Stat
clinical trials
Flu
influenza
baloxavir marboxil
Xofluza
Shionogi
Flag link:
Shire, Shionogi File NDA for Intuniv for Adults in Japan
Shire, Shionogi File NDA for Intuniv for Adults in Japan
Yahoo/Zacks.com
Shire
Shionogi
ADHD
Japan
Intuniv
Flag link:
FDA hustles through a quick OK for Shionogi’s new thrombocytopenia drug
FDA hustles through a quick OK for Shionogi’s new thrombocytopenia drug
Endpoints
Shionogi
Mulpleta
thrombocytopenia
FDA
Flag link:
Roche’s antiviral hits flu targets in PhIII trial
Roche’s antiviral hits flu targets in PhIII trial
Pharma Times
Roche
baloxavir marboxil
antivirals
Flu
Shionogi
Flag link:
The first single-dose flu drug nod could be FDA’s Christmas present for Roche
The first single-dose flu drug nod could be FDA’s Christmas present for Roche
Fierce Pharma
Roche
Shionogi
Xofluza
Flu
FDA
Flag link:
ViiV Healthcare reports positive results for late-stage HIV trials
ViiV Healthcare reports positive results for late-stage HIV trials
Marketwatch
ViiV Healthcare
GSK
Pfizer
Shionogi
HIV
clinical trials
Dolutegravir
lamivudine
Flag link:
On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression
On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression
Endpoints
SAGE Therapeutics
SAGE-217
Asia
Shionogi
depression
Flag link:
Shionogi’s flu drug wins green light in Japan, but U.S. approval not likely until 2019
Shionogi’s flu drug wins green light in Japan, but U.S. approval not likely until 2019
Fierce Pharma
Japan
Shionogi
Flu
influenza
Xofluza
Flag link:
Shionogi, Roche get their first approval for the next big thing in fighting the flu
Shionogi, Roche get their first approval for the next big thing in fighting the flu
Endpoints
Shionogi
Roche
Flu
influenza
Xofluza
Japan
Tamiflu
Flag link:
Japan-based Shionogi develops powerful drug to treat influenza
Japan-based Shionogi develops powerful drug to treat influenza
GoinPharma
Shionogi
influenza
Flag link:
Crestor Developer Sees Sales Doubling On Lower-Priced Drugs
Crestor Developer Sees Sales Doubling On Lower-Priced Drugs
Bloomberg
Crestor
drug pricing
Shionogi
Flag link:
The FDA issues warning letter to Shionogi over co-pay voucher
The FDA issues warning letter to Shionogi over co-pay voucher
Medical Marketing and Media
FDA
warnings
Shionogi
co-pay vouchers
Flag link:
Why ViiV Healthcare leads the pharma industry in corporate reputation
Why ViiV Healthcare leads the pharma industry in corporate reputation
BioPharma Dive
ViiV Healthcare
Pfizer
GSK
Shionogi
AbbVie
Lundbeck
Janssen
Novo Nordisk
Flag link:
Roche looks beyond Tamiflu, striking deal for Shionogi's flu fighter
Roche looks beyond Tamiflu, striking deal for Shionogi's flu fighter
Fierce Pharma
Roche
Tamiflu
Shionogi
Flu
Flag link:
Glaxo’s Best ‘Headache’ Remedy May Be Buying Stakes in Ventures
Glaxo’s Best ‘Headache’ Remedy May Be Buying Stakes in Ventures
Bloomberg
GSK
Advair
Pfizer
Shionogi
Novartis
Flag link:
AstraZeneca and Shionogi extend Crestor license
AstraZeneca and Shionogi extend Crestor license
Reuters
Crestor
AstraZeneca
Shionogi
Flag link:
Targeting An Untapped Female Sexual Dysfunction Drug Market
Targeting An Untapped Female Sexual Dysfunction Drug Market
Seeking Alpha
female sexual dysfunction
Osphena
Shionogi
flibanserin
Sprout Pharmaceuticals
bremelanotide
Palatin
Femprox
Apricus Biosciences
Flag link:
Can This HIV Drug Challenge Gilead's Domination?
Can This HIV Drug Challenge Gilead's Domination?
Motley Fool
Gilead
HIV
ViiV Healthcare
Tivicay
GSK
Shionogi
Pfizer
Flag link:

Pages